A detailed history of Inspire Investing, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Inspire Investing, LLC holds 36,659 shares of EXEL stock, worth $1.33 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
36,659
Previous 29,328 25.0%
Holding current value
$1.33 Million
Previous $761,000 60.32%
% of portfolio
0.14%
Previous 0.08%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$25.39 - $36.46 $186,134 - $267,288
7,331 Added 25.0%
36,659 $1.22 Million
Q3 2024

Oct 10, 2024

BUY
$21.96 - $27.6 $296,108 - $372,158
13,484 Added 85.1%
29,328 $761,000
Q2 2024

Aug 12, 2024

BUY
$20.34 - $23.73 $4,861 - $5,671
239 Added 1.53%
15,844 $356,000
Q1 2024

May 07, 2024

SELL
$20.17 - $23.93 $29,064 - $34,483
-1,441 Reduced 8.45%
15,605 $370,000
Q4 2023

Feb 12, 2024

SELL
$19.25 - $24.13 $267,440 - $335,238
-13,893 Reduced 44.9%
17,046 $408,000
Q3 2023

Oct 26, 2023

SELL
$19.04 - $22.74 $318,520 - $380,417
-16,729 Reduced 35.09%
30,939 $676,000
Q2 2023

Jul 31, 2023

BUY
$18.17 - $20.48 $611,020 - $688,701
33,628 Added 239.52%
47,668 $910,000
Q1 2023

Apr 24, 2023

SELL
$16.3 - $19.41 $11,654 - $13,878
-715 Reduced 4.85%
14,040 $272,000
Q4 2022

Jan 26, 2023

BUY
$14.96 - $17.39 $14,556 - $16,920
973 Added 7.06%
14,755 $0
Q3 2022

Nov 07, 2022

BUY
$15.68 - $22.27 $57,106 - $81,107
3,642 Added 35.92%
13,782 $216,000
Q2 2022

Aug 10, 2022

BUY
$17.44 - $23.16 $176,841 - $234,842
10,140 New
10,140 $211,000
Q2 2020

Aug 12, 2020

SELL
$16.46 - $27.42 $378 - $630
-23 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$14.46 - $21.8 $332 - $501
23 New
23 $0
Q1 2018

Apr 13, 2018

SELL
$22.15 - $31.89 $1,107 - $1,594
-50 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$24.23 - $30.93 $1,211 - $1,546
50
50 $2,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Inspire Investing, LLC Portfolio

Follow Inspire Investing, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Inspire Investing, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Inspire Investing, LLC with notifications on news.